Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Kōichi Goto(National Cancer Center Hospital East), Pasi A. Jänne(Harvard University), Kaline Pereira(Daiichi Sankyo (United States)), Junichi Shimizu(Aichi Cancer Center), Elvire Pons‐Tostivint(Centre Hospitalier Universitaire de Nantes), Kiichiro Ninomiya(Okayama Shoka University), Egbert F. Smit(Dutch Cancer Society), Zenta Tsuchihashi(Daiichi Sankyo (United States)), David Planchard(Université Paris-Saclay), Chih‐Hsi S. Kuo(Chang Gung University), Yasushi Goto(Tennessee Oncology), Myung‐Ju Ahn(Sungkyunkwan University), Ayumi Taguchi(Daiichi-Sankyo (Japan)), Hidetoshi Hayashi(Kindai University), M. Pérol(Centre Léon Bérard), Sang‐We Kim(Ulsan College), James Chih‐Hsin Yang(National Taiwan University Hospital), Toshio Kubo(Okayama University Hospital), Adrianus J. de Langen(The Netherlands Cancer Institute), Dong‐Wan Kim(Seoul National University Hospital), Yingkai Cheng(Daiichi Sankyo (United States)), Silvia Novello(University of Turin), Wenqin Feng(Daiichi Sankyo (United States)), Fu-Chih Cheng(Daiichi Sankyo (United States))
Cited by 293
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k